vs
Side-by-side financial comparison of CareDx, Inc. (CDNA) and Celcuity Inc. (CELC). Click either name above to swap in a different company.
CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $108.4M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | $86.7M | — | ||
| Q1 25 | $84.7M | — | ||
| Q4 24 | $86.6M | — | ||
| Q3 24 | $82.9M | — | ||
| Q2 24 | $92.3M | — | ||
| Q1 24 | $72.0M | — |
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $-8.6M | — | ||
| Q1 25 | $-10.4M | — | ||
| Q4 24 | $87.7M | — | ||
| Q3 24 | $-10.6M | — | ||
| Q2 24 | $-4.6M | — | ||
| Q1 24 | $-19.9M | — |
| Q4 25 | -5.6% | — | ||
| Q3 25 | -0.2% | — | ||
| Q2 25 | -12.8% | — | ||
| Q1 25 | -15.8% | — | ||
| Q4 24 | 97.5% | — | ||
| Q3 24 | -16.6% | — | ||
| Q2 24 | -7.9% | — | ||
| Q1 24 | -31.3% | — |
| Q4 25 | -3.8% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | -9.9% | — | ||
| Q1 25 | -12.2% | — | ||
| Q4 24 | 101.3% | — | ||
| Q3 24 | -12.8% | — | ||
| Q2 24 | -5.0% | — | ||
| Q1 24 | -27.6% | — |
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $1.60 | — | ||
| Q3 24 | $-0.20 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.38 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
